ReviewFrontiers in pharmacology2026
Research progress of exosomes in renal ischemia-reperfusion injury.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal ischemia-reperfusion injury (RIRI), which causes renal damage that occurs when blood flow is restored after a period of reduced perfusion, is a common cause of acute kidney injury. As the disease progresses, treatment options become increasingly limited, highlighting the urgent need for new therapeutic approaches. Among these, exosomes (Exos) have shown great potential in the prevention and treatment of this condition. Exos are nano-sized vesicles of endosomal origin, typically less than 200 nm in diameter, and have emerged as key mediators in diverse pathophysiological processes. This article provides a comprehensive narrative review of the mechanisms of various types of Exos in renal ischemia-reperfusion injury and the advancements in exosome therapy, and details both their renoprotective mechanisms and potential pathogenic effects. Furthermore, we highlight advanced bioengineering strategies, delivery platforms, and diagnostic potential. By explicitly addressing translational barriers and the need for rigorous methodological standardization, we aim to provide comprehensive insights for advancing exosome-based RIRI management from bench to clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.